An "omics" view of drug development

Drug Development Research

Volumn 62, Issue 2, 2004, Pages 81-85

  Altman, Russ B ^a   Rubin, Daniel L ^a   Klein, Teri E ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

GPCRs; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEBRISOQUINE; DOPAMINE; INSULIN; KETOCONAZOLE; MEPHENYTOIN; PHENOBARBITAL; QUINIDINE; TESTOSTERONE; TOLBUTAMIDE; TROLEANDOMYCIN;

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; HUMAN; HUMAN GENOME; INTERNET; MEDLINE; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 9644270474     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10370     Document Type: Review

References (6)

1. Consortium TIH. 2003. The international HapMap project. Nature 426:789-796.
2. Drysdale CM, et al. 2000. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97:10483-10488.
3. Green SA, Rathz DA, Schuster AJ, Liggett SB. 2001. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 421:141-147.
4. Klein TE, Altman RB. 2004. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Pharmacogenomics J 4:1.
5. Rubin D, Altman R. 2004. A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge (submitted).
6. Weinshilboum R. 2001. Thiopurine pharmacogenetics; clinical and molecular studies of thiopurine methyltranslerase. Drug Metab Dispos 29:601-605.